Open in interactive viewer → charts, metric popovers & call review

Spectral AI: The BARDA Bill Comes Due

A cost-share clause guts the margin, guidance drops 30%, and the reimbursement story that's supposed to save 2026 doesn't pay out until late 2027.
MDAI · Earnings Call · 2026-11-10

The contract that flipped from subsidy to surcharge

For three years BARDA was Spectral AI's answer to every skeptical question: $250 million of non-dilutive funding, a de novo clearance in May, a balance sheet that didn't need to beg. In the third quarter that same partner quietly flipped sign. The base phase of the contract completed in June and the company moved into a follow-on phase where scope narrows and costs are shared — BARDA reimburses a portion of development spending and Spectral funds the rest, with the company's share booked into cost of revenue. The arithmetic is brutal in its simplicity. Research and development revenue fell to $2.9 million from $3.8 million, and “Gross margin was 27.2% compared to 42.7% reflecting our share of development costs with BARDA which is recorded in cost of revenue” — David McGuire, Chief Financial Officer · 2026-11-10. Treasurer David McGuire was explicit that this is not a one-quarter artifact: this quarter "would be indicative of our continuing gross margins under that contract." The single largest bull case on this name for two years just became the reason its gross margin broke. The revenue trajectory was already ugly before this. Total revenue is down 45% over three years from a 2025Q1 peak of $7 million. Now management has taken the 2026 outlook down hard:

we are updating our 2026 outlook for research and development revenue of approximately $13 million compared to our previous guidance of approximately $18.5 million. The update primarily reflects 2 things. First, the MTECH program is complete... Second, the timing of development activities reimbursed under the BARDA contract moves revenue into future periods.

David McGuire, Chief Financial Officer · 2026-11-10
That is a 30% haircut, and note what it excludes — no DeepView device sales, no new government awards. Which means the company is asking investors to underwrite a commercial ramp that it has not put a single dollar of guidance behind.

Reimbursement becomes the whole religion

What genuinely changed in the narrative this quarter is where management points the camera. The DeepView AI regulatory saga — de novo submission, FDA clearance, UKCA authorization — dominated the keyword set through 2026Q1. It has now been almost entirely displaced by payment mechanics. The quarter's biggest movers were reimbursement, hospital system, Hospital, physician and a brand-new Triage. That is the language of someone who has a product and needs a payer. The specifics: an NTAP application filed early in Q3 for hospitals only, “we had asked for a reimbursement code to be at $2.75 thousand per patient” — Vincent Stanley Capone, Chief Executive Officer · 2026-11-10 — determination in August 2027, effective October 2027 for a two-to-three year term. Physician-side coding advances to CPT-3 pricing on 01/01/2027, with the migration to CPT 1 gated behind the TNT study that only starts at four to five burn centers in early December. Read the dates plainly: every reimbursement lever that would make a hospital's purchase pencil out matures in 2027 or 2028, not in the year management keeps promising. Worth noting the market backdrop is friendly to exactly this pitch. Reimbursement-code clarity has been a productive theme — permanent J Code events have been among the strongest healthcare movers on the tape over the last year, and reimbursement process sits in the global keyword set. Spectral is riding a real wave. It just happens to be a wave that breaks a year after its cash does.

The 2026 promise that keeps receding

Here is where the transcript history earns its keep. On the March call, asked how the 30 BARDA-supported systems translate into revenue, the CEO said “I don't see that adding a lot to our revenue number for 2026” — Vincent Capone, Chief Executive Officer · 2026-03-24, and separately that “my hope is that we place devices in late 2026” — Vincent Capone, Chief Executive Officer · 2026-03-24. On the August call he disclosed the entire commercial organization: “today our sales force really includes two people” — Vincent Capone, Chief Executive Officer · 2026-08-11, with budget for at least two more. On today's call the same milestone is described as “the initial BARDA supported deployments of our DeepView AI system for our first commercial sales which remain an achievable goal for 2026” — Vincent Stanley Capone, Chief Executive Officer · 2026-11-10. "Achievable goal" is the phrase you use when you have stopped being able to say "expect." And the friction hasn't changed either — the August warning about AI committees and cybersecurity review is now relabeled as procurement process: “going through the procurement hurdle in centers where we don't have a strong relationship will lead us to a longer procurement window” — Vincent Capone, Chief Executive Officer · 2026-08-11. The cost share is real; the commercial sale is still a hope, and the BARDA contract that everyone counted on is now the thing squeezing the P&L. Two quieter tells. First, international slipped: the UKCA refresh that was expected by year-end is now expected in early 2027 — “we now expect this approval in early 27” — Vincent Stanley Capone, Chief Executive Officer · 2026-11-10 — pushing the UK, Australia and GCC launch further out. Second, coverage is thinning. The March call drew BTIG, Northland, H.C. Wainwright and Zacks. Today: two analysts, four and three questions. Sell-side attention has halved alongside a stock that has drifted 18% lower over 90 trading days and sits 90% below its 2023 peak.

The cash clock

Against all of that, the balance sheet is the constraint that matters. Cash stood at $11.2 million versus $15.4 million at year-end, after $10.5 million of operating use offset by $6.3 million of financing. Effective net cash is now marginally negative — the $15 million Avenue facility is fully drawn, interest-only through March 2027, maturing March 2028. Adjusted EBITDA loss was $3.7 million for the quarter. $11.2 million against that burn is roughly three quarters of runway, and the much-advertised $90 million of remaining BARDA funding is milestone-gated, not cash in hand. Which makes the valuation the strangest part of the story. Price to revenue has climbed to 3.6x while revenue fell 30%. Investors are paying up for a reimbursement option that doesn't vest until 2027, funded by a treasury that expires around the same time. The bull case here is not dead — a cleared device, a manufacturing run of 30 units, deep burn-center relationships and a CEO who keeps hammering equitable access regardless of socioeconomic status are not nothing. But the story has inverted. For two years Spectral AI was a company with a government sponsor and a development problem. It is now a company with a commercial problem, a shrinking sponsor, and a clock.